查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1776225

皮膚填充劑的全球市場:洞察，競爭情形，市場預測:2032年年

Dermal Fillers - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2024年，真皮填充劑市場規模達62.3822億美元。預計到2032年，該市場規模將達到116.9543億美元，2025年至2032年的複合年增長率為8.25%。真皮填充劑的需求受多種關鍵因素驅動。首先，全球整容手術數量的增長主要源於人口老化、人們對保持年輕容貌的渴望以及美學意識的不斷提升。其次，與傳統手術相比，微創整形手術因其便利性、更短的恢復時間和更低的成本，正日益受到人們的青睞。最後，研發投入的不斷增加以及真皮填充劑技術的持續創新，也進一步推動了市場的成長。綜合來看，這些因素預計將在2025年至2032年的預測期內推動真皮填充劑市場大幅擴張。

真皮填充劑市場動態：

根據國際美容整形外科學會 (ISAPS, 2024) 的數據，2023年全球共進行了超過3500萬例美容手術，包括手術和非手術。值得注意的是，臉部和頭部手術顯著成長，超過650萬例，比前一年增長19.6%。到2022年，這一成長趨勢將包括超過1,490萬例手術和超過1,880萬例非手術手術，凸顯了全球對美容提升日益增長的需求。

真皮填充劑在此背景下發揮重要作用。填充劑通常與手術配合使用，作為初步增強，或作為術後的改良工具。例如，填充劑通常用於撫平疤痕、恢復臉部體積，以及在拉皮或隆鼻手術後提升臉部特徵。這種整合進一步鞏固了真皮填充劑作為美容醫學領域補充和獨立解決方案的重要性。

全球美容手術的興起是真皮填充劑市場成長的主要驅動力。這一增長是由日益增長的美學意識、向微創治療的轉變以及全球範圍內獲得先進美容手術的管道的改善所推動的。 ISAPS 也指出了強化這一全球動能的區域趨勢。

  • 巴西繼續保持其美容手術領先國家的地位，已實施超過 300 萬例手術。
  • 印度也是美容手術的領先國家之一，報告了 1,028,723 例美容手術，其中 496,931 例為非手術手術，其中很大一部分是真皮填充劑。
  • 美國國立衛生研究院 (2024) 進一步報告稱，印度整形外科醫生實施的非手術面部年輕化手術數量位居世界第二，每年實施的整容手術超過一百萬例。僅在 2022 年，印度就記錄了約 370,656 例整容手術，顯示對手術和非手術手術的需求持續增長。
  • 在英國，根據英國美容整形外科醫生協會 (2023) 的數據，2022 年英國實施了超過 31,057 例整容手術，進一步促進了全球市場的擴張。

為了滿足日益增長的需求，行業領導者正在加強研發力度，以開發具有更高功效、更安全、更持久的下一代真皮填充劑。 2025年4月，Evolus宣布推出Evolysse™ Form和Evolysse™ Smooth兩種可注射透明質酸(HA)凝膠，旨在撫平皺紋、恢復豐盈度，尤其適用於法令紋（從鼻翼到嘴角的皺紋）。

然而，真皮填充劑相關的併發症和安全問題，以及高昂的治療費用，是限制真皮填充劑市場成長的一些主要限制因素。

真皮填充劑市場區隔分析：

在真皮填充劑材料領域，透明質酸 (HA) 預計將在 2024 年佔據最大的市場佔有率。透明質酸 (HA) 在真皮填充劑市場中的成長受到多種關鍵因素的推動，包括 HA 基填充劑的日益普及、全球美容手術數量的增長，以及該類別的廣泛益處和應用。

根據國際美容整形外科學會 (ISAPS, 2023) 的數據，2023 年全球進行了超過 5,564,866 例非手術美容手術，包括使用透明質酸填充劑的手術，高於 2022 年的 4,312,037 例。這一穩定成長主要得益於可支配收入的提高、人們對美容醫療趨勢的認知度不斷提升，以及對外表的日益關注，尤其是在城市居民和千禧世代中。

透明質酸填充劑的主要優點之一是透明質酸是人體內天然存在的物質，可顯著降低過敏反應的風險。這些填充劑以其恢復臉部豐盈度、滋潤肌膚、撫平皺紋和提升臉部輪廓的功效而聞名。玻尿酸填充劑與肌膚無縫融合，帶來自然的外觀和觸感，深受尋求精緻而有效煥膚的患者青睞。

玻尿酸填充劑的另一個優點在於其效果立竿見影。注射後，這些填充劑能夠快速補充體積，減少皺紋，並帶來顯著的美容效果，且無需長時間的恢復期。這種即時效果尤其吸引那些尋求快速、非侵入性改善以適應社交或職業場合的患者。此外，透明質酸填充劑的可逆性是其顯著特點，可增強患者信心並增強醫師的控制力。如果出現不滿意或副作用，可以使用一種名為透明質酸酶的酵素安全地溶解填充劑，從而進一步提高治療的安全性和靈活性。

持續的產品創新和行業領導者的監管審批也為該領域的成長提供了支持。例如，2023年5月，艾伯維（AbbVie）旗下公司艾爾建美學（Allergan Aesthetics）宣布美國FDA批准SKINVIVE™聯合JUVEDERM®，這是一種新型透明質酸皮內注射微滴注射劑，旨在改善21歲及以上成年人的皮膚光滑度。 SKINVIVE™是美國首個也是唯一一個基於透明質酸（HA）的同類療法，在最佳治療條件下，療效可持續長達六個月。

上述因素可能會推動這一細分市場的發展，並最終推動全球真皮填充劑市場的發展。

預計到2024年，北美將在真皮填充劑市場佔據最大佔有率，這主要得益於幾個關鍵因素。這種區域主導地位主要歸因於人口老化和人們對保持年輕外觀的渴望日益增長，導緻美容手術數量不斷增加。此外，對微創美容治療日益增長的需求以及完善的醫療基礎設施也顯著促進了市場成長。人們對美容手術的認知度不斷提高和廣泛接受度也進一步支撐了這一趨勢。此外，市場領先公司批准並推出的眾多產品也鞏固了北美的地位。綜合來看，這些因素預計將在2025年至2032年的預測期內保持北美在真皮填充劑市場的領先地位。

根據國際美容整形外科學會（ISAPS，2023）的數據，美國在美容手術數量方面位居世界首位，共進行了6,196,701例手術，其中包括4,405,599例非手術美容治療。在這些非手術手術中，84,817例使用了羥基磷灰石鈣基填充劑，712,225例使用了透明質酸（HA）真皮填充劑。此外，美國整形外科醫師協會 (2023) 報告稱，2023 年美國共進行了超過 950 萬例整形手術。

美容手術數量的增加是該地區真皮填充劑市場成長的關鍵驅動力。這一增長反映了對非手術、微創治療日益增長的需求，這些治療能夠快速見效且恢復期最短。推動這一增長的因素包括：人們的認知度不斷提高、美容整形的廣泛接受度以及老齡化人口尋求保持年輕容貌的有效解決方案。

此外，主要市場參與者正在加強研發力度，以推出並商業化滿足當地需求的先進真皮填充劑產品。例如，2023 年 6 月，高德美 (Galderma) 宣布美國食品藥物管理局 (FDA) 批准 Restylane® Eyelight，該產品專為治療 21 歲及以上成年人的眼底凹陷（黑眼圈）而設計。該產品是美國首款也是唯一一款採用NASHA®技術配製的透明質酸（HA）真皮填充劑，旨在解決眼底體積減少問題，並實現自然的眼部效果。

同樣，2022年2月，艾伯維（AbbVie）旗下子公司Allergan Aesthetics宣布FDA批准JUVEDERM® VOLBELLA® XC用於治療21歲及以上成年人的眶下窩。這款多功能填充劑還可用於豐唇和矯正口周皺紋，透過縮小眼底凹陷來改善整體臉部美觀。

總而言之，越來越多的美容手術和策略性產品的推出正在推動北美對真皮填充劑的需求，以鞏固其在全球真皮填充劑市場領先地位。

真皮填充劑市場的主要公司

真皮填充劑市場的主要參與者包括 AbbVie Inc.、Galderma、Merz Pharma、Tiger BioSciences、Teoxane SA、Crown Laboratories, Inc.、Prollenium Medical Technologies, Inc.、Johnson & Johnson Services, Inc.、Anika Therapeutics, Inc.、Fillmed、VIVACY LaboratorIinal Inc.、Anika Therapeutics, Inc。 Inc.、Symatese、LG Chem、KORU Pharma Co., Ltd. 和 BIOPLUS CO., Ltd.。

真皮填充劑市場的最新發展：

  • 2025 年 2 月，全球領先的皮膚護理創新公司－私人企業 Crown Laboratories, Inc. 宣布成功收購 Revance Therapeutics。公司是一家專注於真皮填充劑的先鋒生物技術公司。此次收購顯著增強了 Crown 的產品組合，並擴大了其在真皮填充劑市場的全球影響力，尤其體現在 RHA Redensity™ 以及一系列基於 RHA®2、RHA®3 和 RHA®4 的真皮填充劑上。
  • 2024 年 10 月，AbbVie 收購了 Revance Therapeutics, Inc。.Illergan Aesthetics 宣佈在全美推出用於治療太陽穴凹陷的 JUVEDERM® VOLUMA® XC。這款透明質酸 (HA) 填充劑已獲批用於治療 21 歲及以上成年人的中度至重度太陽穴凹陷。作為備受患者和醫療保健提供者青睞的領先 HA 真皮填充劑品牌，JUVEDERM® 填充劑系列現已提供最廣泛的治療適應症，幫助患者實現其美學目標。
  • 2022 年 10 月，Prollenium Medical Technologies Inc. 完成了對 Softfill® 的收購，Softfill® 是一個以先進的微型套管和創新化妝品而聞名的法國先鋒品牌。透過此次策略性收購，Prollenium 透過引入透明質酸基真皮填充劑品牌 Revanesse® 來擴展其產品組合，從而鞏固了其在全球真皮填充劑市場的地位，進一步增強了其提供尖端美學解決方案的能力。

真皮填充劑市場研究報告重點

  • 目前真皮填充劑市場規模分析（2024 年）及八年市場預測（2025-2032 年）
  • 過去三年主要產品/技術開發、併購、合作及合資企業
  • 主導真皮填充劑市場的主要公司
  • 真皮填充劑市場中其他競爭對手面臨的各種機會
  • 2024 年主要細分市場及其未來前景 2032 年這些細分市場的表現
  • 目前真皮填充劑市場中表現最佳的地區和國家
  • 未來公司應關注真皮填充劑市場成長機會的地區和國家

真皮填充劑市場常見問題

1.真皮填充劑

  • 真皮填充劑是一種可注射的物質，用於美容醫學，以恢復肌膚體積、撫平皺紋和細紋，並提升臉部輪廓。它們是一種常見的非手術美容療法，旨在透過填充因衰老、遺傳或環境因素而失去體積和彈性的部位，使臉部和其他身體部位恢復活力。

2. 真皮填充劑市場

  • 預計2024年真皮填充劑市值將達到62.3822億美元，到2032年將達到116.9543億美元，在2025年至2032年的預測期內，複合年增長率為8.25%。

3.真皮填充劑市場的驅動因素

  • 真皮填充劑的需求受到關鍵驅動因素的推動。全球整容手術數量的增長與老齡化社會密切相關，這源於人們日益增強的美學意識以及對保持年輕容貌的渴望。此外，人們越來越傾向於微創治療，因為與傳統手術相比，微創治療具有便利、恢復時間短、成本效益高等優勢。此外，持續的研發投入和真皮填充劑的持續創新，也促進了安全性、有效性和使用壽命更高的先進產品的推出。預計這些趨勢將在2025年至2032年的預測期內推動真皮填充劑市場顯著成長。

4.真皮填充劑市場的主要參與者

  • 真皮填充劑市場的主要參與者包括AbbVie Inc.，Galderma，Merz Pharma，Tiger BioSciences，Teoxane SA，Crown Laboratories, Inc.，Prollenium Medical Technologies, Inc，Johnson &Johnson Services, Inc.，Anika Therapeutics, Inc.，Fillmed，VIVACY Laboratories，Sinclair，Medytox，HUGEL, Inc.，Ipsen Pharma，Evolus, Inc.，Symatese，LG Chem，KORU Pharma Co.LTD.，BIOPLUS 有CO.LTD.等。

5. 真皮填充劑市場最大佔有率的地區

  • 預計到 2024 年，北美將在真皮填充劑市場佔據最大佔有率，這主要受幾個關鍵因素的影響。這種區域主導地位主要歸因於人口老化和保持年輕外觀的願望推動了美容手術數量的增長。此外，對微創美容療程的需求不斷增長以及完善的醫療基礎設施也顯著促進了市場成長。人們對美容手術的認知度不斷提高和廣泛接受度進一步推動了這一趨勢。此外，市場領先公司大量產品的核准和上市也鞏固了北美市場的地位。綜合來看，這些因素預計將在2025年至2032年的預測期內，維持北美在真皮填充劑市場的領先地位。

目錄

第1章 皮膚填充劑市場報告的簡介

第2章 皮膚填充劑市場摘要整理

第3章 競爭情形

第4章 法規分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第5章 皮膚填充劑市場主要原因分析

  • 真皮填充劑市場驅動因素
    • 全球化妝品市場成長手術
    • 微創美容手術需求不斷成長
    • 真皮填充劑研發與創新投入不斷增加
  • 真皮填充劑市場限制與課題
    • 真皮填充劑相關的併發症和安全問題
    • 治療成本較高
  • 真皮填充劑市場的機遇
    • 更先進的可生物降解和可生物吸收填充劑的開發

第6章 皮膚填充劑市場上波特的五力分析

第7章 皮膚填充劑市場評估

  • 各產品類型
    • 生物分解性填充物
    • 非生物分解性填充劑
  • 不同材料
    • 玻尿酸(HA)
    • 烴基磷灰石鈣(CaHA)
    • 多L乳酸(PLLA)
    • 聚甲基丙烯酸甲酯(PMMA)
    • 其他
  • 性別
    • 男性
    • 女性
  • 各終端用戶
    • 醫院
    • 皮膚科診所
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 皮膚填充劑市場企業與產品簡介

  • AbbVie Inc.
  • Galderma
  • Merz Pharma
  • Tiger BioSciences
  • Teoxane SA
  • Crown Laboratories, Inc.
  • Prollenium Medical Technologies, Inc.
  • Johnson & Johnson Services, Inc.
  • Anika Therapeutics, Inc.
  • Fillmed
  • VIVACY Laboratories
  • Sinclair
  • Medytox
  • HUGEL, Inc.
  • Ipsen Pharma
  • Evolus, Inc.
  • Symatese
  • LG Chem
  • KORU Pharma Co., LTD.
  • BIOPLUS CO., LTD.

第9章 KOL的見解

第10章 計劃方法

第11章 關於DelveInsight

第12章 免責聲明和諮詢方式

Product Code: DISR0218

Dermal Fillers Market by Product Type (Biodegradable Fillers and Non-Biodegradable Fillers), Material (Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others), Gender (Male and Female), End-User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising number of cosmetic procedures performed globally and increasing product development and launches activities by key players.

The dermal fillers market was valued at USD 6,238.22 million in 2024, growing at a CAGR of 8.25% during the forecast period from 2025 to 2032 to reach USD 11,695.43 million by 2032. The demand for dermal fillers is driven by several key factors. Firstly, the rising number of cosmetic procedures performed globally is primarily attributed to the aging population and a growing desire to maintain a youthful appearance, alongside increasing aesthetic consciousness. Secondly, there is a strong shift towards minimally invasive cosmetic procedures due to their convenience, shorter recovery times, and lower costs compared to traditional surgeries. Lastly, increasing investments and continuous innovations in the research and development of dermal fillers are further propelling market growth. These factors collectively are expected to drive significant expansion in the dermal fillers market during the forecast period from 2025 to 2032.

Dermal Fillers Market Dynamics:

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS, 2024), in 2023, more than 35 million aesthetic procedures, both surgical and non-surgical, were performed globally. Notably, face and head procedures experienced substantial growth, accounting for over 6.5 million procedures, marking a 19.6% increase from the previous year. In 2022, this upward trend included more than 14.9 million surgical and 18.8 million non-surgical procedures, underscoring the growing global demand for aesthetic enhancements.

Dermal fillers play a critical role in this landscape. They are often used alongside surgical procedures, either as a preliminary enhancement or a post-surgical refinement tool. For instance, fillers are commonly applied to smooth scars, restore facial volume, or enhance features following facelifts or rhinoplasty. This integration further solidifies the relevance of dermal fillers as a complementary and standalone solution in the field of aesthetic medicine.

The rising number of cosmetic procedures worldwide is a key driver of growth in the dermal fillers market. This surge is fueled by increasing aesthetic awareness, a shift toward minimally invasive treatments, and improved accessibility to advanced cosmetic procedures across the globe. ISAPS also highlighted regional trends that reinforce this global momentum. In 2023:

  • Brazil performed over 3 million aesthetic procedures, maintaining its position as one of the major countries in aesthetic procedures.
  • India reported 1,028,723 aesthetic procedures, of which 496,931 were non-surgical, a substantial portion involving dermal fillers, as one of the leading countries in cosmetic procedures.
  • The National Institutes of Health (2024) further reported that India ranked second globally country in the number of non-surgical facial rejuvenation procedures performed by plastic surgeons, with over 1 million aesthetic procedures conducted annually. In 2022 alone, the country recorded approximately 370,656 cosmetic surgeries, showcasing sustained demand across surgical and non-surgical procedures.
  • In the United Kingdom, data from the British Association of Aesthetic Plastic Surgeons (2023) showed that, in 2022, over 31,057 cosmetic procedures were conducted, further contributing to the global expansion of the market.

In response to rising demand, key industry players are intensifying R&D efforts to develop next-generation dermal fillers that offer improved efficacy, safety, and longevity. A notable example is Evolus, which in April 2025 announced the commercial launch of Evolysse(TM) Form and Evolysse(TM) Smooth, an injectable hyaluronic acid (HA) gels designed to smooth wrinkles and restore volume, particularly in areas such as the nasolabial folds (lines running from the nose to the corners of the mouth).

However, the complications and safety concerns associated with dermal fillers and high treatment cost, among others are some of the key constraints that may limit the growth of the dermal fillers market.

Dermal Fillers Market Segment Analysis:

Dermal Fillers Market by Product Type (Biodegradable Fillers and Non-Biodegradable Fillers), Material (Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others), Gender (Male and Female), End-User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the material segment of the dermal fillers market, the hyaluronic acid (HA) category is estimated to account for the largest market share in 2024. The growth of the hyaluronic acid (HA) segment within the dermal fillers market is being propelled by several key factors, including the increasing adoption of HA-based fillers, the rising number of aesthetic procedures worldwide, and the wide range of benefits and applications associated with this category.

According to the International Society of Aesthetic Plastic Surgery (ISAPS, 2023), over 5,564,866 non-surgical cosmetic procedures involving hyaluronic acid-based dermal fillers were performed globally in 2023, up from 4,312,037 procedures in 2022. This steady upward trend is largely driven by growing disposable incomes, heightened awareness of cosmetic treatments, and an increasing focus on personal appearance, particularly among urban and millennial populations.

One of the primary advantages of HA-based fillers is that hyaluronic acid is a naturally occurring substance in the body, which significantly reduces the risk of allergic reactions. These fillers are well-known for their ability to restore facial volume, hydrate the skin, smooth wrinkles, and enhance facial contours. HA fillers integrate seamlessly with the skin, delivering a natural look and feel that appeals to patients seeking subtle yet effective rejuvenation.

Another important benefit of HA fillers is their capacity to provide immediate visible results. Upon injection, these fillers quickly replenish volume and reduce wrinkles, offering noticeable cosmetic improvements without extended downtime. This instant gratification is especially attractive to patients who desire quick, non-invasive enhancements for social or professional occasions. Furthermore, the reversibility of HA fillers is a standout feature that enhances patient confidence and physician control. In cases of dissatisfaction or adverse reactions, the filler can be safely dissolved using an enzyme called hyaluronidase, providing an added layer of safety and flexibility in treatment.

The segment's growth is also supported by continuous product innovations and regulatory approvals from leading industry players. For example, in May 2023, Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of SKINVIVE(TM) by JUVEDERM(R), a novel hyaluronic acid intradermal microdroplet injection designed to improve skin smoothness in adults over 21. SKINVIVE(TM) is the first and only HA-based treatment of its kind available in the U.S., offering results that can last up to six months with optimal treatment.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of dermal fillers across the globe.

North America is expected to dominate the overall dermal fillers market:

North America is projected to hold the largest share of the dermal fillers market in 2024, driven by several key factors. This regional dominance can be primarily attributed to the rising number of cosmetic procedures performed, fueled by an aging population and an increasing desire to maintain a youthful appearance. Additionally, the growing demand for minimally invasive cosmetic treatments, coupled with a well-established healthcare infrastructure, has significantly contributed to market growth. Increased awareness and widespread acceptance of aesthetic procedures further support this trend. Moreover, numerous product approvals and new launches by leading market players are strengthening North America's position. Collectively, these factors are expected to sustain North America's leadership in the dermal fillers market throughout the forecast period from 2025 to 2032.

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS, 2023), the United States led the world in the number of aesthetic procedures performed, with 6,196,701 total procedures, including 4,405,599 non-surgical cosmetic treatments. Among these non-surgical procedures, 84,817 involved Calcium Hydroxylapatite-based fillers, while 712,225 utilized hyaluronic acid (HA) dermal fillers. Additionally, the American Society of Plastic Surgeons (2023) reported that over 9.5 million plastic surgeries were performed in the U.S. in 2023.

The rising volume of aesthetic procedures is a significant driver of the dermal fillers market growth in the region. This increase reflects growing demand for non-surgical, minimally invasive treatments that offer quick results and minimal downtime. The surge is fueled by heightened awareness, broader acceptance of cosmetic enhancements, and an expanding aging population seeking effective solutions for maintaining a youthful appearance.

Furthermore, key market players are intensifying their research and development efforts to introduce and commercialize advanced dermal filler products tailored to meet regional needs. For example, in June 2023, Galderma announced the U.S. Food and Drug Administration (FDA) approval of Restylane(R) Eyelight, designed specifically for the treatment of under-eye hollows (dark shadows) in adults over 21. This product is the first and only HA dermal filler in the U.S. formulated with NASHA(R) Technology to address volume loss under the eyes, delivering natural-looking results.

Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, announced FDA approval for JUVEDERM(R) VOLBELLA(R) XC to treat infraorbital hollows in adults over 21. This versatile filler is also used for lip augmentation and correction of perioral lines, enhancing overall facial aesthetics by improving the appearance of under-eye hollows.

Collectively, the increasing volume of cosmetic procedures combined with strategic product launches is propelling the demand for dermal fillers in North America, solidifying its position as a leading region in the global dermal fillers market.

Dermal Fillers Market Key Players:

Some of the key market players operating in the dermal fillers market include AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and others.

Recent Developmental Activities in the Dermal Fillers Market:

  • In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity(TM) and its range of RHA(R) 2, RHA(R) 3, and RHA(R) 4 based dermal fillers.
  • In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVEDERM(R) VOLUMA(R) XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVEDERM(R) Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals.
  • In October 2022, Prollenium Medical Technologies Inc. completed the acquisition of SoftFil(R), a pioneering French brand known for its advanced micro-cannulas and innovative cosmetic products. Through this strategic acquisition, Prollenium strengthened its position in the global dermal fillers market by expanding its portfolio with Revanesse(R), a brand of hyaluronic acid-based dermal fillers, further enhancing its capabilities in delivering cutting-edge aesthetic solutions.

Key takeaways from the dermal fillers market report study

  • Market size analysis for current dermal fillers market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the dermal fillers market.
  • Various opportunities available for the other competitors in the dermal fillers market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current dermal fillers market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for dermal fillers market growth in the coming future?

Target audience who can benefit from this dermal fillers market report study

  • Dermal filler product providers
  • Research organizations and consulting companies
  • Dermal fillers-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in dermal fillers
  • Various end-users who want to know more about the dermal fillers market and the latest technological developments in the dermal fillers market.

Frequently Asked Questions for the Dermal Fillers Market:

1. What are dermal fillers?

  • Dermal fillers are injectable substances used in aesthetic medicine to restore volume, smooth out wrinkles and fine lines, and enhance facial contours. They are a popular non-surgical cosmetic treatment designed to rejuvenate the face and other areas by filling in areas that have lost volume or elasticity due to aging, genetics, or environmental factors.

2. What is the market for dermal fillers?

  • The dermal fillers market was valued at USD 6,238.22 million in 2024, growing at a CAGR of 8.25% during the forecast period from 2025 to 2032 to reach USD 11,695.43 million by 2032.

3. What are the drivers for the dermal fillers market?

  • The demand for dermal fillers is being fuelled by key drivers. The growing number of cosmetic procedures worldwide is closely linked to an aging population and a heightened desire among individuals to preserve a youthful appearance, supported by rising aesthetic awareness. Further, there is an increasing preference for minimally invasive treatments that offer the benefits of convenience, reduced recovery time, and cost-effectiveness compared to traditional surgical options. In addition, sustained investment and ongoing innovation in dermal filler research and development are contributing to the introduction of advanced products with improved safety, efficacy, and longevity. Together, these trends are expected to drive substantial growth in the dermal fillers market over the forecast period from 2025 to 2032.

4. Who are the key players operating in the dermal fillers market?

  • Some of the key market players operating in the dermal fillers market include AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and others.

5. Which region has the highest share in the dermal fillers market?

  • North America is projected to hold the largest share of the dermal fillers market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising number of cosmetic procedures performed, fueled by an aging population and an increasing desire to maintain a youthful appearance. Additionally, the growing demand for minimally invasive cosmetic treatments, coupled with a well-established healthcare infrastructure, has significantly contributed to market growth. Increased awareness and widespread acceptance of aesthetic procedures further support this trend. Moreover, numerous product approvals and new launches by leading market players are strengthening North America's position. Collectively, these factors are expected to sustain North America's leadership in the dermal fillers market throughout the forecast period from 2025 to 2032.

Table of Contents

1. Dermal Fillers Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Dermal Fillers Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Dermal Fillers Market Key Factors Analysis

  • 5.1. Dermal Fillers Market Drivers
    • 5.1.1. The rising number of cosmetic procedures performed globally
    • 5.1.2. The increasing demand for minimally invasive cosmetic procedures
    • 5.1.3. Increasing investments and innovations in the research and development of dermal fillers
  • 5.2. Dermal Fillers Market Restraints and Challenges
    • 5.2.1. Complications and safety concerns associated with dermal fillers
    • 5.2.2. High treatment cost
  • 5.3. Dermal Fillers Market Opportunity
    • 5.3.1. Development of more advanced biodegradable and bioresorbable fillers

6. Dermal Fillers Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Dermal Fillers Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Biodegradable Fillers
    • 7.1.2. Non-Biodegradable Fillers
  • 7.2. By Material
    • 7.2.1. Hyaluronic Acid (HA)
    • 7.2.2. Calcium hydroxylapatite (CaHA)
    • 7.2.3. Poly-L-lactic acid (PLLA)
    • 7.2.4. Polymethylmethacrylate (PMMA)
    • 7.2.5. Others
  • 7.3. By Gender
    • 7.3.1. Male
    • 7.3.2. Female
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Dermatology Clinics
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.3. India Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.4.3. South America Dermal Fillers Market Size In USD Million (2022-2032)

8. Dermal Fillers Market Company and Product Profiles

  • 8.1. AbbVie Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Galderma
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Merz Pharma
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Tiger BioSciences
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Teoxane SA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Crown Laboratories, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Prollenium Medical Technologies, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Johnson & Johnson Services, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Anika Therapeutics, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Fillmed
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. VIVACY Laboratories
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Sinclair
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Medytox
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. HUGEL, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Ipsen Pharma
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Evolus, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Symatese
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. LG Chem
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. KORU Pharma Co., LTD.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. BIOPLUS CO., LTD.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Dermal Fillers Market in Global (2022-2032)
  • Table 3: Dermal Fillers Market in Global by Product Type (2022-2032)
  • Table 4: Dermal Fillers Market in Global by Material (2022-2032)
  • Table 5: Dermal Fillers Market in Global by Gender (2022-2032)
  • Table 6: Dermal Fillers Market in Global by End-User (2022-2032)
  • Table 7: Dermal Fillers Market in Global by Geography (2022-2032)
  • Table 8: Dermal Fillers Market in North America (2022-2032)
  • Table 9: Dermal Fillers Market in the United States (2022-2032)
  • Table 10: Dermal Fillers Market in Canada (2022-2032)
  • Table 11: Dermal Fillers Market in Mexico (2022-2032)
  • Table 12: Dermal Fillers Market in Europe (2022-2032)
  • Table 13: Dermal Fillers Market in France (2022-2032)
  • Table 14: Dermal Fillers Market in Germany (2022-2032)
  • Table 15: Dermal Fillers Market in United Kingdom (2022-2032)
  • Table 16: Dermal Fillers Market in Italy (2022-2032)
  • Table 17: Dermal Fillers Market in Spain (2022-2032)
  • Table 18: Dermal Fillers Market in the Rest of Europe (2022-2032)
  • Table 19: Dermal Fillers Market in Asia-Pacific (2022-2032)
  • Table 20: Dermal Fillers Market in China (2022-2032)
  • Table 21: Dermal Fillers Market in Japan (2022-2032)
  • Table 22: Dermal Fillers Market in India (2022-2032)
  • Table 23: Dermal Fillers Market in Australia (2022-2032)
  • Table 24: Dermal Fillers Market in South Korea (2022-2032)
  • Table 25: Dermal Fillers Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: Dermal Fillers Market in the Rest of the World (2022-2032)
  • Table 27: Dermal Fillers Market in the Middle East (2022-2032)
  • Table 28: Dermal Fillers Market in Africa (2022-2032)
  • Table 29: Dermal Fillers Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Dermal Fillers Market in Global (2022-2032)
  • Figure 3: Dermal Fillers Market in Global by Product Type (2022-2032)
  • Figure 4: Dermal Fillers Market in Global by Material (2022-2032)
  • Figure 5: Dermal Fillers Market in Global by Gender (2022-2032)
  • Figure 6: Dermal Fillers Market in Global by End-User (2022-2032)
  • Figure 7: Dermal Fillers Market in Global by Geography (2022-2032)
  • Figure 8: Dermal Fillers Market in North America (2022-2032)
  • Figure 9: Dermal Fillers Market in the United States (2022-2032)
  • Figure 10: Dermal Fillers Market in Canada (2022-2032)
  • Figure 11: Dermal Fillers Market in Mexico (2022-2032)
  • Figure 12: Dermal Fillers Market in Europe (2022-2032)
  • Figure 13: Dermal Fillers Market in France (2022-2032)
  • Figure 14: Dermal Fillers Market in Germany (2022-2032)
  • Figure 15: Dermal Fillers Market in United Kingdom (2022-2032)
  • Figure 16: Dermal Fillers Market in Italy (2022-2032)
  • Figure 17: Dermal Fillers Market in Spain (2022-2032)
  • Figure 18: Dermal Fillers Market in the Rest of Europe (2022-2032)
  • Figure 19: Dermal Fillers Market in Asia-Pacific (2022-2032)
  • Figure 20: Dermal Fillers Market in China (2022-2032)
  • Figure 21: Dermal Fillers Market in Japan (2022-2032)
  • Figure 22: Dermal Fillers Market in India (2022-2032)
  • Figure 23: Dermal Fillers Market in Australia (2022-2032)
  • Figure 24: Dermal Fillers Market in South Korea (2022-2032)
  • Figure 25: Dermal Fillers Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: Dermal Fillers Market in the Rest of the World (2022-2032)
  • Figure 27: Dermal Fillers Market in the Middle East (2022-2032)
  • Figure 28: Dermal Fillers Market in Africa (2022-2032)
  • Figure 29: Dermal Fillers Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis